or Try an Advanced Search...

    Technical Analysis for ABVC - ABVC Biopharma, Inc.

    Grade Last Price % Change Price Change
    C 0.66 -4.49% -0.03
    ABVC closed down 4.49 percent on Friday, November 1, 2024, on 1.15 times normal volume. It was able to find support at its 50 day moving average.
    Earnings due: Nov 13
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Flat
    Historical ABVC trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Calm After Storm Range Contraction -4.49%
    Upper Bollinger Band Walk Strength -4.49%
    Wide Bands Range Expansion -4.49%
    Overbought Stochastic Strength -4.49%
    Gapped Down Weakness -4.49%
    Older End-of-Day Signals for ABVC ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 23 hours ago
    Rose Above Previous Day's High 1 day ago
    Up 3% 1 day ago
    Up 2% 1 day ago
    Up 1% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ABVC Chart by TradingView
    Basic chart:

    Profile

    ABVC Biopharma, Inc. Description

    American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Pancreatic Cancer Depression Major Depressive Disorder Myelodysplastic Syndrome Attention Deficit Hyperactivity Disorder Treatment Of Pancreatic Cancer Triple Negative Breast Cancer

    Is ABVC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 22 ABVC BioPharma receives $50,000 in incremental licensing fees, shares climb
    Oct 22 ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
    Aug 16 ABVC BioPharma GAAP EPS of -$0.09
    Aug 15 ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
    Jul 2 ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
    Jun 25 ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
    Jun 21 ABVC Biopharma files to sell 1M shares of common stock for holders
    Jun 12 ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
    May 24 Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
    May 22 ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
    See more ABVC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.22
    52 Week Low 0.4053
    Average Volume 147,283
    200-Day Moving Average 0.94
    50-Day Moving Average 0.64
    20-Day Moving Average 0.60
    10-Day Moving Average 0.66
    Average True Range 0.07
    RSI (14) 52.83
    ADX 29.11
    +DI 24.82
    -DI 14.43
    Chandelier Exit (Long, 3 ATRs) 0.56
    Chandelier Exit (Short, 3 ATRs) 0.62
    Upper Bollinger Bands 0.77
    Lower Bollinger Band 0.43
    Percent B (%b) 0.69
    BandWidth 56.42
    MACD Line 0.02
    MACD Signal Line 0.00
    MACD Histogram 0.0165
    Fundamentals Value
    Market Cap 5.22 Million
    Num Shares 7.91 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -0.18
    Price-to-Sales 14.34
    Price-to-Book 1.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.79
    Resistance 3 (R3) 0.79 0.76 0.77
    Resistance 2 (R2) 0.76 0.73 0.76 0.76
    Resistance 1 (R1) 0.71 0.71 0.69 0.70 0.75
    Pivot Point 0.67 0.67 0.67 0.67 0.67
    Support 1 (S1) 0.62 0.64 0.61 0.62 0.57
    Support 2 (S2) 0.59 0.62 0.59 0.56
    Support 3 (S3) 0.54 0.59 0.55
    Support 4 (S4) 0.53